Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature

Published:2020-09-28 Issue:1 Volume:68 Page:96-102
ISSN:2051-3895
Container-title:Journal of Medical Radiation Sciences
language:en
Short-container-title:J Med Radiat Sci

Author:

Dasgupta Archya¹²³,Sahgal Arjun¹²³,Warner Ellen⁴⁵,Czarnota Gregory J.¹²³⁶^ORCID

Affiliation:

1. Department of Radiation Oncology Sunnybrook Health Sciences Centre Toronto Ontario Canada

2. Department of Radiation Oncology University of Toronto Toronto Ontario Canada

3. Physical Sciences Sunnybrook Research Institute Toronto Ontario Canada

4. Department of Medical Oncology Sunnybrook Health Sciences Centre Toronto Ontario Canada

5. Department of Medicine University of Medicine Toronto Ontario Canada

6. Department of Medical Biophysics University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Radiology Nuclear Medicine and imaging,Radiological and Ultrasound Technology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmrs.435

Reference24 articles.

1. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

2. Palbociclib and Letrozole in Advanced Breast Cancer

3. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

4. HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

5. Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice;McCartney A;Front Oncol,2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Ultrasensitive Electrochemical Sensor Using Banana Peel Activated Carbon/NiFe₂O₄/MnCoFe-LDH Nanocomposites for Anticancer Drug Determination;ACS Omega;2024-06-12

2. Combining radiation and systemic therapy;Palliative Radiation Oncology;2024

3. Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature;Current Oncology;2023-06-06

4. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer;Radiotherapy and Oncology;2022-12

5. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study;International Journal of Radiation Oncology*Biology*Physics;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3